Regulus Therapeutics
RGLS
RGLS was delisted on the 24th of June, 2025.
0 hedge funds and large institutions have $760 invested in Regulus Therapeutics in 2025 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 75 closing their positions.
82.36% less ownership
Funds ownership: 82.36% → 0% (-82%)
100% less funds holding
Funds holding: 75 → 0 (-75)
100% less capital invested
Capital invested by funds: $107M → $760 (-$107M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 75
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $224K
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$39.2M |
| 2 |
NMC
NEA Management Company
Timonium,
Maryland
|
-$11.3M |
| 3 |
OCA
Octagon Capital Advisors
New York
|
-$8.11M |
| 4 |
BlackRock
New York
|
-$7.3M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$6.92M |
RGLS Hedge Fund Activity: Q2 2025 in Review
0 of the 7,612 institutional investors tracked by Wall St. Rank reported a position in Regulus Therapeutics (RGLS) for Q2 2025, worth a combined $760 — down 100% from $107M a quarter earlier.
Sellers outnumbered buyers: 75 funds closed out of RGLS and 0 opened new positions — a net loss of 75 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Federated Hermes, exiting entirely with an estimated $39.2M sold.
- 0 institutional investors held Regulus Therapeutics (RGLS) as of Q2 2025, down from 75 in Q1 2025.
- Funds reported $760 of Regulus Therapeutics stock for Q2 2025, down 100% quarter-over-quarter.
- 0 funds opened new Regulus Therapeutics positions in Q2 2025 and 75 closed out, a net change of -75 holders.
- The largest Regulus Therapeutics seller in Q2 2025 was Federated Hermes, an estimated $39.2M sold.
Based on aggregated 13F filings for Q2 2025.